The Brain Resource Company (ASX:BRC) is to supply its services to a Schering Israel funded Multiple Sclerosis study.

The Brain Resource Company (ASX:BRC) has been granted approval from the US FDA to market its methodology and standardised international human brain database.

Following its recent Nasdaq listing, Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has appointed the president and CEO of New Jersey-based Chugai Pharma USA, David J Mazzo, as a non-executive director.

GlaxoSmithKline Research and Development is to buy two Brain Resource Laboratories from Sydney-based brain function databasecompiler Brain Resource Company (ASX:BRC), for operation at Quintiles' Guys Drug Research Unit in London.

Sydney-based Brain Resource Company (ASX: BRC) has completed an AUD$4 million placement to institutional investors, giving it the funding to back a marketing push for its brain imaging and functional testing products and services.

Sydney-based Brain Resource Company (ASX:BRC) has cracked into the biotechnology sector with a deal to provide its profiles of brain function and cognition to Biogen in the United States.